Estée Lauder Companies
EL
$93.30
+1.45%
The Estée Lauder Companies Inc. is a global leader in the prestige beauty market, operating across skin care (49% of fiscal 2025 sales), makeup (29%), fragrance (17%), and hair care and other categories (5%), with a portfolio of iconic brands including Estée Lauder, Clinique, M.A.C, La Mer, Jo Malone London, Aveda, Bobbi Brown, and Origins. The company sells through department stores, travel retail, specialty beauty retailers, freestanding stores, e-commerce, salons/spas, and perfumeries across more than 150 countries, generating 31% of revenue from the Americas, 37% from Europe, the Middle East and Africa (including travel retail), and 32% from Asia-Pacific. The current investor narrative centers on a turnaround story: after a prolonged period of earnings pressure and a failed merger discussion with Puig, management has pivoted to an independent restructuring plan focused on cost discipline, inventory reduction, and margin recovery. Recent headlines highlight that the turnaround is gaining traction, with accelerating sales and expanding margins driving renewed optimism, though the stock remains well below its 52-week high as investors debate the durability of the recovery amid a challenging global prestige beauty demand environment.…
EL
Estée Lauder Companies
$93.30
Related headlines
Investment Opinion: Should I buy EL Today?
Rating: Hold. The core thesis is that Estée Lauder is a credible turnaround story with improving revenue and margins, but the current valuation already reflects much of the recovery, and the risk/reward is balanced rather than compelling. The analyst consensus is 'buy' with a mean rating of 2.3 and an average target of $107.13, implying 16.5% upside, but the wide target range ($70–$127) and the split between Buy and Hold ratings underscore the execution uncertainty.
Supporting evidence includes: (1) revenue growth of 6.33% YoY in Q4 FY2026, a clear inflection from prior declines; (2) gross margin expansion to 75.46% from 72.00%, with operating margin improving to 7.00% from 4.13%; (3) TTM free cash flow of $1.316 billion and cash of $3.498 billion, providing financial flexibility; and (4) a forward PE of 23.51x, which is reasonable if the estimated EPS of $4.25 is achieved, though the trailing PE of 157.9x and EV/EBITDA of 20.86x highlight how much recovery is priced in. The PS ratio of 1.90x is near multi-year lows, offering some valuation support.
The biggest risks that could invalidate the thesis are: (1) a failure to sustain margin gains, which would make the forward earnings estimate unreachable and trigger multiple compression; (2) a dividend cut due to the unsustainable 279% payout ratio, which would hurt income-oriented investors and signal deeper problems; and (3) a slowdown in Asia-Pacific or travel retail, which together represent a significant portion of revenue. The rating would upgrade to Buy if the company delivers two consecutive quarters of positive net income and revenue growth above 5%, or if the stock pulls back below $80 (implying a forward PE below 19x). It would downgrade to Sell if revenue growth turns negative again or if operating margin fails to hold above 6%. Relative to its own history, the stock is undervalued on a PS basis but fairly valued on forward earnings; relative to peers, it trades at a premium that is justified only by a successful turnaround.
Sign up to view all
EL 12-Month Price Forecast
Estée Lauder is a credible turnaround story with tangible operational improvements, but the stock is fairly valued at $91.97 given the execution risks. The forward PE of 23.51x assumes a successful recovery, and while the analyst consensus is bullish, the split ratings and wide target range reflect genuine uncertainty. The base case (55% probability) sees the stock reaching $100-$115 as earnings meet expectations, but the bear case (20% probability) could see a retest of $66-$75 if growth stalls. I would upgrade to bullish if the company delivers two consecutive quarters of positive net income and revenue growth above 5%, and downgrade to bearish if operating margin falls below 6% or revenue growth turns negative.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Estée Lauder Companies's 12-month outlook, with a consensus price target around $107.66 and implied upside of +15.4% versus the current price.
Average Target
$107.66
0 analysts
Implied Upside
+15.4%
vs. current price
Analyst Count
—
covering this stock
Price Range
$70 - $127
Analyst target range
The stock is covered by 28 analysts, with a consensus recommendation of "buy" (recommendation mean of 2.3 on a scale where 1 is Strong Buy and 5 is Strong Sell). The average price target is $107.13, which implies approximately 16.5% upside from the current price of $91.97. The consensus leans bullish, but the distribution of ratings shows a mix: recent institutional ratings include Buy/Overweight from Goldman Sachs, JP Morgan, Citigroup, and Piper Sandler, while Equal Weight/Neutral/Hold ratings come from Barclays, Morgan Stanley, Telsey Advisory Group, Jefferies, Canaccord Genuity, and UBS. This split suggests that while the sell-side is generally constructive, there is significant caution among analysts regarding the pace and sustainability of the turnaround. The target price range spans from a low of $70.00 to a high of $127.00, a wide spread of $57.00 that signals high uncertainty. The high target of $127.00 implies a bullish scenario where the turnaround accelerates, margins expand significantly, and the company successfully navigates the challenging prestige beauty environment, potentially with multiple expansion as earnings recover. The low target of $70.00, which is close to the 52-week low of $66.22, prices in a scenario where the recovery stalls, competitive pressures intensify, or macroeconomic headwinds (particularly in Asia travel retail) weigh on results. The wide spread indicates that analysts have divergent views on the company's ability to execute its turnaround, and the recent institutional ratings show no major upgrades or downgrades, suggesting a wait-and-see approach. Given the high short ratio of 1.82, there is some short interest that could fuel a squeeze if positive catalysts emerge, but the overall sentiment remains cautiously optimistic with significant execution risk.
Bulls vs Bears: EL Investment Factors
The bull case rests on tangible turnaround progress—6.33% revenue growth, 346 basis points of gross margin expansion, and a narrowing net loss—supported by a consensus buy rating and 16.5% average analyst upside. The bear case centers on the still-weak profitability (1.21% TTM net margin, 4.78% ROE), a stretched balance sheet (D/E of 2.43), and a dividend that is not covered by earnings (279% payout ratio). Currently, the bull evidence has the stronger near-term momentum, as the operational improvements are measurable and the analyst community remains constructive, but the bear case is not easily dismissed given the valuation already embeds a successful recovery. The single most important tension is whether the margin recovery can be sustained and translated into consistent positive net income—if it can, the forward PE of 23.51x will prove conservative; if it cannot, the stock risks a sharp de-rating back toward the 52-week low of $66.22.
Bullish
- Turnaround gains traction with accelerating sales: Q4 FY2026 revenue rose 6.33% YoY to $3.627 billion, marking a positive inflection after prior declines. The sequential trend (Q1 $3.481B, Q2 $4.229B, Q3 $3.712B, Q4 $3.627B) shows stabilization, and the recent 33.06% six-month price gain reflects growing investor confidence in the recovery.
- Margin recovery is well underway: Gross margin expanded to 75.46% in Q4 FY2026 from 72.00% a year earlier, while operating margin improved to 7.00% from 4.13%. The net loss narrowed to $116 million (EPS -$0.32) from a $546 million loss (EPS -$1.51), demonstrating meaningful cost discipline and operating leverage.
- Analyst consensus sees 16.5% upside: With 28 analysts covering the stock, the consensus recommendation is 'buy' (mean 2.3) and the average price target is $107.13, implying 16.5% upside from $91.97. The high target of $127.00 suggests a bull case of roughly 38% upside if the turnaround accelerates.
- Valuation is undemanding on forward earnings: The forward PE of 23.51x is reasonable for a global prestige beauty leader with iconic brands, especially versus the distorted trailing PE of 157.9x. The PS ratio of 1.90x is near the low end of its multi-year range (down from over 20x in 2022), suggesting the market has already de-rated the stock significantly.
Bearish
- Elevated leverage and dividend sustainability risk: The debt-to-equity ratio of 2.43 and current ratio of 1.22 indicate a heavily leveraged balance sheet with only adequate short-term liquidity. The payout ratio of 279% far exceeds earnings, meaning the 1.78% dividend yield is not covered by net income and could be cut if the recovery stalls.
- Profitability remains weak with negative earnings: The TTM net margin is just 1.21% and ROE is a paltry 4.78%, reflecting the lingering impact of restructuring charges and operational inefficiencies. Q4 FY2026 still posted a net loss of $116 million, and the company has not yet demonstrated consistent positive quarterly earnings.
- Valuation prices in a flawless recovery: The forward PE of 23.51x and EV/EBITDA of 20.86x are elevated relative to the current low earnings base, leaving little room for disappointment. If estimated EPS of $4.25 for the coming year is not achieved, the stock could suffer significant multiple compression.
- Recent price weakness and relative underperformance: Despite a 33.06% six-month gain, the stock is down 9.08% over the past month and 13.85% year-to-date, underperforming the S&P 500 by 26.71 percentage points YTD. The 1-year relative strength versus SPY is -11.41%, indicating the longer-term trend remains challenged.
EL Technical Analysis
Estée Lauder is in a recovery phase within a broader range-bound consolidation. The stock trades at $91.97, representing 47.1% of its 52-week range (low of $66.22, high of $121.64), and has gained 3.60% over the past year, significantly underperforming the S&P 500's 15.01% advance. This positioning—mid-range but with a positive 1-year return—suggests the stock has stabilized after a severe drawdown (max drawdown of -43.79%) but has not yet reclaimed the momentum that would signal a full trend reversal. The 6-month change of +33.06% and 3-month change of +9.87% indicate a strong intermediate-term recovery, yet the year-to-date decline of -13.85% and 1-month drop of -9.08% reveal that the stock has recently given back a meaningful portion of those gains, creating a divergence between the longer-term recovery and short-term weakness. Relative strength versus SPY is negative over 1-month (-9.67%) and 1-year (-11.41%) but positive over 3-month (+6.53%) and 6-month (+15.71%), confirming that the stock's outperformance is concentrated in the recent past while longer-term relative performance remains challenged. Key technical levels are defined by the 52-week low at $66.22 (support) and the 52-week high at $121.64 (resistance); a breakout above $121.64 would signal a full trend reversal and likely attract momentum buyers, while a breakdown below $66.22 would indicate a resumption of the downtrend and potential capitulation. With a beta of 1.274, the stock is approximately 27% more volatile than the broader market, meaning position sizing should account for amplified moves in both directions; the current price of $91.97 sits roughly 39% above the 52-week low and 24% below the 52-week high, placing it in the upper-middle of its range where resistance is more proximate than support.
Beta
1.26
1.26x market volatility
Max Drawdown
-43.8%
Largest decline past year
52-Week Range
$66-$122
Price range past year
Annual Return
+6.0%
Cumulative gain past year
| Period | EL Return | S&P 500 |
|---|---|---|
| 1m | -10.2% | +0.6% |
| 3m | +10.5% | +3.6% |
| 6m | +30.6% | +14.6% |
| 1y | +6.0% | +15.8% |
| ytd | -12.6% | +13.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
EL Fundamental Analysis
Revenue has shown signs of stabilization and modest growth, with the most recent quarter (Q4 FY2026, ended June 30, 2026) delivering $3.627 billion in revenue, up 6.33% year-over-year. This compares favorably to the prior-year quarter's $3.411 billion and reflects a multi-quarter trend of gradual recovery: Q3 FY2026 revenue was $3.712 billion, Q2 FY2026 was $4.229 billion, and Q1 FY2026 was $3.481 billion, with the year-over-year growth rate turning positive after prior declines. Segment data for the most recent quarter shows skin care as the largest contributor at $1.853 billion, followed by makeup at $1.010 billion, fragrance at $618 million, and hair care at $140 million, indicating that the core skin care and makeup categories are driving the top-line recovery. The growth trajectory, while modest, is a critical improvement for a company that had been struggling with declining sales in prior periods, and it supports the narrative that the turnaround strategy is beginning to yield results. Profitability remains under pressure but is improving. In Q4 FY2026, the company reported a net loss of $116 million (EPS of -$0.32), a significant improvement from the prior-year Q4 net loss of $546 million (EPS of -$1.51), demonstrating a narrowing loss trajectory. Gross margin for the quarter was 75.46%, up from 72.00% in the prior-year quarter, and operating margin improved to 7.00% from 4.13% a year earlier, though it remains below the double-digit levels seen in healthier periods. The trailing twelve-month net margin is just 1.21%, and the operating margin is 11.14%, reflecting the lingering impact of restructuring charges and operational inefficiencies, but the direction of travel is positive. The balance sheet carries meaningful leverage, with a debt-to-equity ratio of 2.43 and a current ratio of 1.22, indicating adequate short-term liquidity but elevated financial risk. Free cash flow on a trailing twelve-month basis is $1.316 billion, and the company generated $576 million in operating cash flow in Q4 FY2026 alone, with free cash flow of $425 million for that quarter. Cash at end of period stood at $3.498 billion, providing a cushion, but the high debt load and a payout ratio of 279% (dividend yield 1.78%) suggest the dividend may be at risk if earnings do not continue to recover. ROE is a low 4.78%, and ROA is 5.23%, reflecting the capital-intensive nature of the business and the drag from recent losses; the company's ability to internally fund growth is improving but remains constrained by debt servicing and dividend obligations.
Quarterly Revenue
$3.6B
2026-06
Revenue YoY Growth
+6.3%
YoY Comparison
Gross Margin
75.5%
Latest Quarter
Free Cash Flow
$1.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is EL Overvalued?
Because Estée Lauder reported positive trailing net income on a TTM basis (EPS of $0.0064), the PE ratio is the primary metric, though the trailing PE of 157.9x is distorted by the very low earnings base and is not meaningful for comparison. The forward PE of 23.51x is far more relevant, as it reflects the market's expectation of a substantial earnings recovery, with estimated EPS of $4.25 for the coming year. The gap between the trailing PE (157.9x) and forward PE (23.51x) implies the market is pricing in a dramatic earnings rebound, which is consistent with the turnaround narrative but also leaves little room for disappointment. On a price-to-sales basis, the stock trades at 1.90x TTM sales, which is more stable and suggests a moderate valuation relative to the company's revenue base. Compared to the broader Household & Personal Products industry, Estée Lauder's forward PE of 23.51x and PS of 1.90x appear to be at a premium to some peers but a discount to others, depending on the peer set; the EV/EBITDA of 20.86x is elevated and reflects the current low EBITDA base. The PB ratio of 7.52x is high, indicating that the market values the brand portfolio and intangible assets well above book value, which is typical for prestige beauty companies with strong brand equity. The premium valuation is justified only if the company can deliver on its earnings recovery; otherwise, the stock could be vulnerable to multiple compression. Historically, Estée Lauder's valuation has been volatile, with the PE ratio ranging from negative territory during loss periods to over 400x in 2023, and the PS ratio has declined from over 20x in 2022 to the current 1.90x, reflecting the significant de-rating that occurred as growth stalled. The current PS ratio of 1.90x is near the low end of its multi-year range, which could signal a value opportunity if the turnaround succeeds, but it also reflects the market's skepticism about the company's growth prospects. The forward PE of 23.51x is above the historical average for the stock during stable periods (typically in the 20-30x range), suggesting that the market is already pricing in a successful recovery; if earnings fail to materialize, the stock could see further downside.
PE
157.9x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 31x~169x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
20.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are significant. The debt-to-equity ratio of 2.43 and current ratio of 1.22 indicate a leveraged balance sheet with limited short-term cushion, while the payout ratio of 279% means the dividend is being funded from sources other than current earnings, raising the risk of a cut. Profitability remains fragile: the TTM net margin is just 1.21%, ROE is 4.78%, and Q4 FY2026 still produced a net loss of $116 million, so the company is dependent on continued margin expansion to justify its valuation. Additionally, revenue is concentrated in skin care (49% of sales) and in the Asia-Pacific/travel retail channel (32% of revenue), making the company vulnerable to a slowdown in Chinese consumer spending or travel retail destocking.
Market and competitive risks are also material. The stock trades at a forward PE of 23.51x and EV/EBITDA of 20.86x, which are premium multiples relative to the current earnings base and leave little room for execution missteps; any disappointment in the earnings recovery could trigger multiple compression. The prestige beauty market is highly competitive, with nimble indie brands and mass-market players encroaching on share, and Estée Lauder's heavy reliance on department stores and travel retail exposes it to structural channel shifts. With a beta of 1.274, the stock is 27% more volatile than the market, and the recent 1-month decline of 9.08% (underperforming SPY by 9.67 percentage points) shows how quickly sentiment can reverse. Macro headwinds, including a strong dollar and uneven global consumer demand, could further pressure results.
The worst-case scenario would be a stall in the turnaround: revenue growth decelerates, margin gains reverse due to competitive discounting, and the company misses its forward EPS estimate of $4.25, leading analysts to downgrade the stock and the market to re-rate it toward the low target of $70.00 or the 52-week low of $66.22. From the current price of $91.97, that represents a downside of approximately 24% to $70.00 and 28% to $66.22. In a more severe scenario where the dividend is cut and restructuring charges persist, the stock could retest the max drawdown level of -43.79%, implying a price near $51.70, a loss of roughly 44% from current levels.
FAQ
The key risks are: (1) Financial risk: high debt-to-equity of 2.43 and a payout ratio of 279% mean the dividend is not covered by earnings and could be cut, while the current ratio of 1.22 provides only adequate liquidity. (2) Execution risk: the turnaround depends on sustaining margin gains; Q4 FY2026 still posted a net loss of $116 million, and the TTM net margin is just 1.21%. (3) Macro and competitive risk: with 32% of revenue from Asia-Pacific and travel retail, a slowdown in Chinese consumer spending or travel retail destocking could hurt results, and competition from indie brands is intensifying. (4) Valuation risk: the forward PE of 23.51x leaves little room for disappointment, and a miss on the $4.25 EPS estimate could trigger a sharp de-rating. Ranked by severity, the execution and financial risks are most immediate.
Our 12-month forecast has three scenarios: Bull case (25% probability) targets $115-$127, driven by accelerating revenue growth above 8% and operating margin reaching double digits. Base case (55% probability) targets $100-$115, assuming revenue growth of 4-6% and EPS meeting the $4.25 consensus. Bear case (20% probability) targets $66-$75, if the recovery stalls, revenue turns negative, and the dividend is cut. The base case is most likely, with the key assumption that the company continues to deliver gradual margin improvement and meets earnings expectations. The analyst average target of $107.13 aligns with our base case range.
EL appears fairly valued on forward earnings but expensive on trailing metrics. The forward PE of 23.51x is in line with the broader market and reflects the expected earnings recovery, while the trailing PE of 157.9x is distorted by the low earnings base. The PS ratio of 1.90x is near the low end of its multi-year range (down from over 20x in 2022), suggesting the market has already de-rated the stock significantly. Compared to peers in the Household & Personal Products industry, EL trades at a premium on EV/EBITDA (20.86x) but a discount on PS. The valuation implies the market expects a successful turnaround; if earnings disappoint, the stock could see further multiple compression.
From a risk/reward perspective, EL is a moderate buy for investors with a long-term horizon and tolerance for volatility. The stock trades at $91.97, with a consensus analyst target of $107.13 implying 16.5% upside, and the forward PE of 23.51x is reasonable if the company achieves its estimated EPS of $4.25. However, the biggest downside risk is a stall in the turnaround, which could send the stock back toward the 52-week low of $66.22, a 28% decline. The dividend yield of 1.78% is attractive but at risk given the 279% payout ratio. For investors who believe in the prestige beauty recovery and can hold through volatility, the risk/reward is favorable, but it is not a low-risk investment.
EL is better suited for long-term investment (minimum 2-3 years) rather than short-term trading. The company is in the early-to-middle stages of a turnaround, and the full benefits of restructuring will take time to materialize. The stock's beta of 1.274 means it is 27% more volatile than the market, making it risky for short-term traders, and the recent 1-month decline of 9.08% illustrates this volatility. The dividend yield of 1.78% is modest and at risk, so income is not a primary reason to hold. Earnings visibility is improving but still uncertain, with a wide analyst target range. A long-term holder can potentially capture the recovery in margins and earnings, but should be prepared for drawdowns and monitor the turnaround progress quarterly.